NEW YORK (GenomeWeb) – ACT Genomics said this week it has completed a round of equity financing from a group of international investors that was co-led by CLSA Capital Partners. The company did not disclose the size of the funding round. The new funding will support ACT's plan to expand its business across Asia, including opening additional CAP-accredited NGS laboratories in Hong Kong, commencing new product R&D, expanding clinical services in Asia, and collaborating on drug development with biopharmaceutical partners.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.